keyword
MENU ▼
Read by QxMD icon Read
search

Prostate carcinoma

keyword
https://www.readbyqxmd.com/read/29772622/-delay-in-high-grade-metastatic-prostate-cancer-progression-by-dutasteride-a-case-report
#1
Yuya Yamada, Hiroshi Fujiwara, Shinya Somiya, Shohei Fujikawa, Yuki Kamiyama, Masahiro Tamaki, Toshio Kanaoka
An 84-year-old man was referred to our hospital with swollen right cervical lymph nodes. Computed tomography showed right supraclavicular and mediastinal lymph node enlargement, and fluorodeoxyglucose positronemissiontomography showed multiple areas of abnormally increased radioactivity inthe right supraclavicular and mediastinal lymph nodes, right ninth rib, and left fifth and seventh ribs. Biopsy of the right supraclavicular lymph node revealed metastatic adenocarcinoma with partial immunohistochemical staining for prostate specific antigen (PSA)...
April 2018: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29772620/-development-of-ectopic-adrenocorticotropic-hormone-syndrome-in-a-patient-with-prostate-cancer-during-combined-androgen-blockade-therapy
#2
Yosuke Sekii, Mitsuhiro Yoshinaga, Masahiro Nakagawa, Hidefumi Kishikawa, Kazumasa Oka, Kenji Nishimura
A 74-year old man presented to us with difficulty urinating. The laboratory examinations revealed an elevated prostate-specific antigen (PSA) level. A prostate biopsy revealed prostate adenocarcinoma. The computed tomography scan showed metastasis to lymph nodes in the pelvic cavity and both adrenal glands. Combined androgen blockade therapy was started, and PSA levels began to decrease gradually. However, 2 months later, he was hospitalized for treatment of cellulitis and was found to have hypertension, hyperglycemia, and hypokalemia...
April 2018: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29772102/novel-nomograms-for-castration-resistant-prostate-cancer-and-survival-outcome-in-patients-with-de-novo-bone-metastatic-prostate-cancer
#3
Jinge Zhao, Guangxi Sun, Banghua Liao, Xingming Zhang, Cameron M Armstrong, Xiaoxue Yin, Jiandong Liu, Junru Chen, Yaojing Yang, Peng Zhao, Qidun Tang, Zhenghao Wang, Zhibin Chen, Xiong Li, Qiang Wei, Xiang Li, Ni Chen, Allen C Gao, Pengfei Shen, Hao Zeng
OBJECTIVES: To develop nomograms predicting the incidence of castration resistant prostate cancer (CRPC) and overall survival (OS) for de novo metastatic prostate cancer (mPCa). MATERIALS AND METHODS: Data from 449 de novo mPCa patients were retrospectively analyzed. Patients were randomly divided into the training (n=314, 70%) and validation cohort (n=135, 30%). Predictive factors were selected by Cox-proportional model and further used for building predictive models...
May 17, 2018: BJU International
https://www.readbyqxmd.com/read/29771950/biophotonic-detection-of-high-order-chromatin-alterations-in-field-carcinogenesis-predicts-risk-of-future-hepatocellular-carcinoma-a-pilot-study
#4
Richard Kalman, Andrew Stawarz, David Nunes, Di Zhang, Mart A Dela Cruz, Arpan Mohanty, Hariharan Subramanian, Vadim Backman, Hemant K Roy
PURPOSE: Hepatocellular carcinoma (HCC) results from chronic inflammation/cirrhosis. Unfortunately, despite use of radiological/serological screening techniques, HCC ranks as a leading cause of cancer deaths. Our group has used alterations in high order chromatin as a marker for field carcinogenesis and hence risk for a variety of cancers (including colon, lung, prostate, ovarian, esophageal). In this study we wanted to address whether these chromatin alterations occur in HCC and if it could be used for risk stratification...
2018: PloS One
https://www.readbyqxmd.com/read/29771007/dichlorophenylacrylonitriles-as-ahr-ligands-displaying-selective-breast-cancer-cytotoxicity-in-vitro
#5
Jennifer R Baker, Jayne Gilbert, Stefan Paula, Xiao Zhu, Jennette A Sakoff, Adam McCluskey
Knoevenagel condensation of 3,4-dichloro- and 2,6-dichloro- phenylacetonitriles gave a library of dichlorophenylacrylonitriles. Our leads 5 and 6 displayed 0.56±0.03 and 0.127±0.04 μM growth inhibition (GI₅₀) and 260-fold selectivity for the MCF-7 breast cancer cell line. A 2,6-dichlorophenyl moiety saw a 10-fold potency loss; additional nitrogen moieties (-NO₂) enhanced activity (26 and 27), with the corresponding -NH₂ analogues (29 and 30) more potent. Despite this, both 29 (2.8±0.03 μM) and 30 (2...
May 17, 2018: ChemMedChem
https://www.readbyqxmd.com/read/29770233/metastasis-to-paranasal-sinuses-from-carcinoma-of-prostate-report-of-a-case-and-review-of-the-literature
#6
Elio Bittar Barbosa, Evaldo César Macau Furtado Ferreira, Fernanda Viviane Mariano, Albina Messias de Almeida Milani Altemani, Emerson Taro Inoue Sakuma, Eulalia Sakano
Metastasis from distant primary tumors is extremely rare in the paranasal sinuses with few hundred cases in the literature. Metastatic carcinoma of the prostate is even rarer, despite being one of the most common tumors, with only 24 cases published. In this article, we report a case of a 58-year-old male presenting with epistaxis and nasal obstruction as initial symptoms of a metastatic prostate carcinoma in the ethmoid cells and maxillary sinus.
2018: Case Reports in Otolaryngology
https://www.readbyqxmd.com/read/29765626/a-focused-library-synthesis-and-cytotoxicity-of-quinones-derived-from-the-natural-product-bolinaquinone
#7
Azadeh Ghods, Jayne Gilbert, Jennifer R Baker, Cecilia C Russell, Jennette A Sakoff, Adam McCluskey
Bolinaquinone is a natural product that is a structurally complex, cytotoxic sesquiterpene quinone. A scaffold simplification and focused library approach using a microwave-assisted Suzuki coupling gave 32 bolinaquinone analogues with good-to-excellent cytotoxicity profiles. Mono-arylbenzoquinones, Library A , were preferentially toxic towards BE2-C (neuroblastoma) cells with growth inhibition (GI50 ) values of 4-12 µM; only the 3,4-dimethoxyphenyl 23 and 3-biphenyl 28 variants were broad-spectrum active-HT29 (colon carcinoma), U87 and SJ-G2 (glioblastoma), MCF-7 (breast carcinoma), A2780 (ovarian carcinoma), H460 (lung carcinoma), A431 (skin carcinoma), Du145 (prostate carcinoma), BE2-C (neuroblastoma), MIA (pancreatic carcinoma) and SMA (spontaneous murine astrocytoma)...
April 2018: Royal Society Open Science
https://www.readbyqxmd.com/read/29763615/anticancer-activity-study-of-a-3-adenosine-receptor-agonists
#8
Gabriella Marucci, Claudia Santinelli, Michela Buccioni, Aleix Martí Navia, Catia Lambertucci, Anastasia Zhurina, Olli Yli-Harja, Rosaria Volpini, Meenakshisundaram Kandhavelu
AIMS: A3 adenosine receptor (A3 AR) signalling activation seems to mediate anticancer effect, and it has been targeted for drug development. The identification of potent and selective A3 AR agonists could be crucial for cancer drug development. MATERIALS AND METHODS: In the present study was determined the in vitro activity of known 1-3 and newly 4-6 synthesized compounds with high A3 AR affinity and selectivity (Ki in the low nanomolar range) in binding studies...
May 13, 2018: Life Sciences
https://www.readbyqxmd.com/read/29762647/maternal-low-protein-diet-impairs-prostate-growth-in-young-rat-offspring-and-induces-prostate-carcinogenesis-with-aging
#9
Sergio A A Santos, Ana C Camargo, Flávia B Constantino, Ketlin T Colombelli, Fernanda Mani, Jaqueline C Rinaldi, Suelen Franco, Luiz M F Portela, Bruno O S Duran, Wellerson R Scarano, Barry T Hinton, Sergio L Felisbino, Luis A Justulin
Carcinogenesis is frequently linked to genetic background, however, exposure to environmental risk factors has gained attention as the etiologic agent for several types of cancer, including prostate. The intrauterine microenvironment has been described as a preponderant factor for offspring health; and maternal exposure to insult has been linked to chronic disease in older offspring. Using a model of maternal exposure to low protein diet (LPD; 6% protein), we demonstrated that impairment of offspring rat prostatic growth on postnatal day (PND) 21 was associated with prostate carcinogenesis in older offspring (PND 540)...
May 14, 2018: Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
https://www.readbyqxmd.com/read/29761525/ets2-is-a-prostate-basal-cell-marker-and-is-highly-expressed-in-prostate-cancers-aberrantly-expressing-p63
#10
Alba Torres, Mohammed Alshalalfa, Elai Davicioni, Anuj Gupta, Srinivasan Yegnasubramanian, Sarah J Wheelan, Jonathan I Epstein, Angelo M De Marzo, Tamara L Lotan
BACKGROUND: Rare prostate carcinomas aberrantly express p63 and have an immunophenotype intermediate between basal and luminal cells. Here, we performed gene expression profiling on p63-expressing prostatic carcinomas and compared them to usual-type adenocarcinoma. We identify ETS2 as highly expressed in p63-expressing prostatic carcinomas and benign prostate basal cells, with lower expression in luminal cells and primary usual-type adenocarcinomas. METHODS: A total of 8 p63-expressing prostate carcinomas at radical prostatectomy were compared to 358 usual-type adenocarcinomas by gene expression profiling performed on formalin fixed paraffin embedded tumor tissue using Affymetrix 1...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29755557/evaluation-of-silibinin-effects-on-the-viability-of-hepg2-human-hepatocellular-liver-carcinoma-and-huvec-human-umbilical-vein-endothelial-cell-lines
#11
Niki Vakili Zahir, Maryam Nakhjavani, Parastoo Hajian, Farshad H Shirazi, Hamidreza Mirzaei
Human hepatocellular carcinoma is one of the most common recurrent malignancies since there is no effective therapy for it. Silibinin, a widely used drug and supplement for various liver disorders, demonstrated anti-cancer effects on human hepatocellular carcinoma, human prostate adenocarcinoma cells, human breast carcinoma cells, human ectocervical carcinoma cells, and human colon cancer cells. Considering the anti-hepatotoxic activity of silibinin and its strong preventive and anti-cancer efficacy against various epithelial cancers, we investigated the efficacy of silibinin against human HCC and HUVEC cell lines...
2018: Iranian Journal of Pharmaceutical Research: IJPR
https://www.readbyqxmd.com/read/29755405/dual-paraneoplastic-endocrine-syndromes-heralding-onset-of-extrapulmonary-small-cell-carcinoma-a-case-report-and-narrative-review
#12
Jill B Feffer, Natalia M Branis, Jeanine B Albu
Objective: Extrapulmonary small cell carcinoma (EPSCC) is rare and frequent metastases at presentation can complicate efforts to identify a site of origin. In particular, SCC comprises <1% of prostate cancers and has been implicated in castration resistance. Methods: Clinical, laboratory, imaging, and pathology data are presented. Results: A 56-year-old man with locally advanced prostate adenocarcinoma on androgen deprivation therapy presented with a clogged nephrostomy tube...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29755357/-n-glycosylation-of-lipocalin-2-is-not-required-for-secretion-or-exosome-targeting
#13
Erawan Borkham-Kamphorst, Eddy Van de Leur, Steffen K Meurer, Eva M Buhl, Ralf Weiskirchen
Lipocalin 2 (LCN2) is a highly conserved secreted adipokine acting as a serum transport protein for small hydrophobic molecules such as fatty acids and steroids. In addition, LCN2 limits bacterial growth by sequestering iron-containing siderophores and further protects against intestinal inflammation and tumorigenesis associated with alterations in the microbiota. Human LCN2 contains one N -glycosylation site conserved in other species. It was postulated that this post-translational modification could facilitate protein folding, protects from proteolysis, is required for proper trafficking from the Golgi apparatus to the cell surface, and might be relevant for effective secretion...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29753463/de-novo-urologic-malignancies-in-renal-transplant-recipients
#14
H Antunes, E Tavares-da-Silva, R Oliveira, J Carvalho, B Parada, C Bastos, A Figueiredo
BACKGROUND: Immunosuppressed organ transplant patients have an elevated risk of malignancies. The aim of this study was to determine the incidence of urologic malignancies in renal transplant recipients, as well as to evaluate their monitoring, treatment, and outcomes. METHODS: We conducted a retrospective single-center study of 2897 renal transplants between January 1987 and December 2016. Recipients presenting with de novo urologic malignancies were evaluated...
March 10, 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29752021/hyperthermic-treatment-at-56-%C3%A2-c-induces-tumour-specific-immune-protection-in-a-mouse-model-of-prostate-cancer-in-both-prophylactic-and-therapeutic-immunization-regimens
#15
Francesco De Sanctis, Sara Sandri, Matteo Martini, Marta Mazzocco, Alessandra Fiore, Rosalinda Trovato, Stefano Garetto, Davide Brusa, Stefano Ugel, Silvia Sartoris
Most active cancer immunotherapies able to induce a long-lasting protection against tumours are based on the activation of tumour-specific cytotoxic T lymphocytes (CTLs). Cell death by hyperthermia induces apoptosis followed by secondary necrosis, with the production of factors named "danger associated molecular pattern" (DAMP) molecules (DAMPs), that activate dendritic cells (DCs) to perform antigen uptake, processing and presentation, followed by CTLs cross priming. In many published studies, hyperthermia treatment of tumour cells is performed at 42-45 °C; these temperatures mainly promote cell surface expression of DAMPs...
May 8, 2018: Vaccine
https://www.readbyqxmd.com/read/29736561/the-utility-of-18-f-dasa-23-for-molecular-imaging-of-prostate-cancer-with-positron-emission-tomography
#16
Corinne Beinat, Tom Haywood, Yun-Sheng Chen, Chirag B Patel, Israt S Alam, Surya Murty, Sanjiv Sam Gambhir
PURPOSE: There is a strong, unmet need for superior positron emission tomography (PET) imaging agents that are able to measure biochemical processes specific to prostate cancer. Pyruvate kinase M2 (PKM2) catalyzes the concluding step in glycolysis and is a key regulator of tumor growth and metabolism. Elevation of PKM2 expression was detected in Gleason 8-10 tumors compared to Gleason 6-7 carcinomas, indicating that PKM2 may potentially be a marker of aggressive prostate cancer. We have recently reported the development of a PKM2-specific radiopharmaceutical [18 F]DASA-23 and herein describe its evaluation in cell culture and preclinical models of prostate cancer...
May 7, 2018: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/29736318/androgen-receptor-signaling-regulates-t-type-ca-2-channel-expression-and-neuroendocrine-differentiation-in-prostate-cancer-cells
#17
Megan Hall, Bryan Todd, Edwin D Allen, Nga Nguyen, Yoon-Jung Kwon, Vu Nguyen, Jennifer L Hearne, Miguel Martin-Caraballo
Therapies designed to reduce androgen production or receptor activation are effective in limiting prostate tumor growth. However, prolonged treatment with anti-androgen therapies results in the progression of prostate cancers into an androgen refractory state. Neuroendocrine differentiation (NED) has been associated with the progression of prostate cancers to an androgen resistant phenotype. In this work we investigated the effect of disrupting androgen receptor signaling in promoting NED of prostate carcinoma cells and whether it is accompanied by an increase in T-type Ca2+ channel expression...
2018: American Journal of Cancer Research
https://www.readbyqxmd.com/read/29734118/multidose-formulation-of-ready-to-use-177-lu-psma-617-in-a-centralized-radiopharmacy-set-up
#18
Sudipta Chakraborty, K V Vimalnath, Rubel Chakravarty, H D Sarma, Ashutosh Dash
Lutetium-177-labeled PSMA inhibitor has emerged as a promising modality for targeted therapy of prostate carcinoma. A protocol for regular multidose formulation of ready-to-use 177 Lu-PSMA-617 has been developed based on detailed and systematic radiochemical investigations. The formulation meets the requirements of clinical use and can be shipped to nuclear medicine centres for administration up to 4 days from the date of formulation. The reported protocol would be useful toward facilitating widespread clinical utilization of 177 Lu-PSMA-617 in the management of prostate cancer...
April 26, 2018: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/29733771/phase-ib-trial-with-birabresib-a-small-molecule-inhibitor-of-bromodomain-and-extraterminal-proteins-in-patients-with-selected-advanced-solid-tumors
#19
Jeremy Lewin, Jean-Charles Soria, Anastasios Stathis, Jean-Pierre Delord, Solange Peters, Ahmad Awada, Philippe G Aftimos, Mohamed Bekradda, Keyvan Rezai, Zhen Zeng, Azher Hussain, Susan Perez, Lillian L Siu, Christophe Massard
Purpose Birabresib (MK-8628/OTX015) is a first-in-class bromodomain inhibitor with activity in select hematologic tumors. Safety, efficacy, and pharmacokinetics of birabresib were evaluated in patients with castrate-resistant prostate cancer, nuclear protein in testis midline carcinoma (NMC), and non-small-cell lung cancer in this phase Ib study. Patients and Methods Forty-seven patients were enrolled to receive birabresib once daily at starting doses of 80 mg continuously (cohort A) or 100 mg for 7 consecutive days (cohort B) in 21-day cycles using a parallel dose escalation 3 + 3 design...
May 7, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29733540/fabp4-suppresses-proliferation-and-invasion-of-hepatocellular-carcinoma-cells-and-predicts-a-poor-prognosis-for-hepatocellular-carcinoma
#20
Cheng-Qian Zhong, Xiu-Ping Zhang, Ning Ma, Er-Bin Zhang, Jing-Jing Li, Ya-Bo Jiang, Yu-Zhen Gao, Yan-Mei Yuan, Shi-Qian Lan, Dong Xie, Shu-Qun Cheng
Adipocyte fatty acid-binding protein (FABP4) is abundant in macrophage and adipocyte. It is known to be involved in lipid metabolism. The role of FABP4 has been reported in various cancers, such as non-small cell lung cancer, breast cancer, ovarian cancer, and prostatic cancer. However, its role remains unclear in hepatocellular carcinoma (HCC). In our study, we investigated the expression of FABP4 at both mRNA and protein levels, and by examining 175 cases of patients with cancer of the liver tissue microarray, the significance between the expression of FABP4 and clinical characteristics had been discussed...
May 7, 2018: Cancer Medicine
keyword
keyword
19764
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"